IDH1 Mutation
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB16267 | Olutasidenib | An isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation as detected by an FDA-approved test. |
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB11793 | Niraparib | 0 | Recruiting | 1 |
| DB13874 | Enasidenib | 1 | Recruiting | 1 |
| DB12500 | Fedratinib | 1 | Recruiting | 1 |
| DB14568 | Ivosidenib | 1 | Recruiting | 1 |
| DB14769 | Pamiparib | 1 / 2 | Completed | 1 |
| DB00853 | Temozolomide | 1 / 2 | Completed | 1 |
| DB14568 | Ivosidenib | 2 | Completed | 1 |
| DB09035 | Nivolumab | 2 | Completed | 1 |
| DB16267 | Olutasidenib | 2 | Not Yet Recruiting | 1 |
| DB00853 | Temozolomide | 2 | Not Yet Recruiting | 1 |